Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 10

PMID 35681755

Authors

Frank Rojas

Edwin Roger Parra

Ignacio Ivan Wistuba

Cara Haymaker

Luisa Maren Solis Soto

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer incidence and mortality worldwide. Adjuvant and neoadjuvant chemotherapy have been used in the perioperative setting of non-small-cell carcinoma (NSCLC); however, the five-year survival rate only improves by about 5%. Neoadjuvant treatment with immune checkpoint inhibitors (ICIs) has become significant due to improved survival in advanced NSCLC patients treated with immunotherapy agents. The assessment of pathology response has been proposed as a surrogate indicator of the benefits of neaodjuvant therapy. An outline of recommendations has been published by the International Association for the Study of Lung Cancer (IASLC) for the evaluation of pathologic response (PR). However, recent studies indicate that evaluations of immune-related changes are distinct in surgical resected samples from patients treated with immunotherapy. Several clinical trials of neoadjuvant immunotherapy in resectable NSCLC have included the study of biomarkers that can predict the response of therapy and monitor the response to treatment. In this review, we provide relevant information on the current recommendations of the assessment of pathological responses in surgical resected NSCLC tumors treated with neoadjuvant immunotherapy, and we describe current and potential biomarkers to predict the benefits of neoadjuvant immunotherapy in patients with resectable NSCLC.

Citing Articles

Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer.

Zhang N, Li C, Zhao Z, Jiang B, Wang W, Sun F Front Immunol. 2025; 16:1497004.

PMID: 39931056 PMC: 11808021. DOI: 10.3389/fimmu.2025.1497004.

PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.

Gureviciene G, Matulione J, Poskiene L, Miliauskas S, Zemaitis M Medicina (Kaunas). 2024; 60(3).

PMID: 38541208 PMC: 10972066. DOI: 10.3390/medicina60030482.

Extracellular vesicles in gastric cancer: role of exosomal lncRNA and microRNA as diagnostic and therapeutic targets.

Jiang C, Zhang J, Wang W, Shan Z, Sun F, Tan Y Front Physiol. 2023; 14:1158839.

PMID: 37664422 PMC: 10469264. DOI: 10.3389/fphys.2023.1158839.

Extracellular RNA profiles in non-small cell lung cancer plasma.

Ni Y, Zhang W, Mu G, Gu Y, Wang H, Wei K J Thorac Dis. 2023; 15(5):2742-2753.

PMID: 37324105 PMC: 10267934. DOI: 10.21037/jtd-23-517.

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.

Yang Y, Liu H, Chen Y, Xiao N, Zheng Z, Liu H Cell Death Dis. 2023; 14(3):230.

PMID: 37002211 PMC: 10066332. DOI: 10.1038/s41419-023-05757-5.

References

Vansteenkiste J, Wauters E, Reymen B, Ackermann C, Peters S, De Ruysscher D . Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019; 30(8):1244-1253. DOI: 10.1093/annonc/mdz175. View

Altorki N, McGraw T, Borczuk A, Saxena A, Port J, Stiles B . Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. 2021; 22(6):824-835. DOI: 10.1016/S1470-2045(21)00149-2. View

Menzies A, Amaria R, Rozeman E, Huang A, Tetzlaff M, van de Wiel B . Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021; 27(2):301-309. DOI: 10.1038/s41591-020-01188-3. View

Nishijima T, Muss H, Shachar S, Moschos S . Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev. 2016; 45:30-7. DOI: 10.1016/j.ctrv.2016.02.006. View

Parra E, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher S . Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018; 6(1):48. PMC: 5989476. DOI: 10.1186/s40425-018-0368-0. View

Kidman J, Principe N, Watson M, Lassmann T, Holt R, Nowak A . Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Front Immunol. 2020; 11:587014. PMC: 7591700. DOI: 10.3389/fimmu.2020.587014. View

Huang J, Xu B, Mo H, Zhang W, Chen X, Wu D . Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. Clin Cancer Res. 2018; 24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. View

Ling Y, Li N, Li L, Guo C, Wei J, Yuan P . Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. NPJ Precis Oncol. 2020; 4(1):32. PMC: 7708412. DOI: 10.1038/s41698-020-00135-2. View

Tizhoosh H, Pantanowitz L . Artificial Intelligence and Digital Pathology: Challenges and Opportunities. J Pathol Inform. 2019; 9:38. PMC: 6289004. DOI: 10.4103/jpi.jpi_53_18. View

10.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

11.

Zhou W, Qu Z, Song C, Sun Y, Lai A, Luo M . NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens. Database (Oxford). 2019; 2019. PMC: 6901387. DOI: 10.1093/database/baz128. View

12.

Pataer A, Weissferdt A, Vaporciyan A, Correa A, Sepesi B, Wistuba I . Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. 2021; 16(8):1289-1297. DOI: 10.1016/j.jtho.2021.03.029. View

13.

Skoulidis F, Goldberg M, Greenawalt D, Hellmann M, Awad M, Gainor J . Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. Cancer Discov. 2018; 8(7):822-835. PMC: 6030433. DOI: 10.1158/2159-8290.CD-18-0099. View

14.

Rooks M, Garrett W . Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6):341-52. PMC: 5541232. DOI: 10.1038/nri.2016.42. View

15.

Caushi J, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E . Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature. 2021; 596(7870):126-132. PMC: 8338555. DOI: 10.1038/s41586-021-03752-4. View

16.

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

17.

Zhong W, Chen K, Chen C, Gu C, Wang J, Yang X . Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. J Clin Oncol. 2019; 37(25):2235-2245. DOI: 10.1200/JCO.19.00075. View

18.

Ren S, Xu A, Lin Y, Camidge D, Di Maio M, Califano R . A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future. Transl Lung Cancer Res. 2021; 10(7):3264-3275. PMC: 8350086. DOI: 10.21037/tlcr-21-259. View

19.

Campesato L, Barroso-Sousa R, Jimenez L, Correa B, Sabbaga J, Hoff P . Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget. 2015; 6(33):34221-7. PMC: 4741447. DOI: 10.18632/oncotarget.5950. View

20.

Stankovic B, Bjorhovde H, Skarshaug R, Aamodt H, Frafjord A, Muller E . Immune Cell Composition in Human Non-small Cell Lung Cancer. Front Immunol. 2019; 9:3101. PMC: 6367276. DOI: 10.3389/fimmu.2018.03101. View